Related Experiment Video
Updated: Feb 28, 2026

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Foundations of an Ovine Model of Fragile X Syndrome
Victoria Hawkins1, Skye R Rudiger2, Clive J McLaughlan2
1Applied Translational Genetics Group, School of Biological Sciences, University of Auckland, Auckland 1010, New Zealand.
Background:
Fragile X Syndrome (FXS) is an X-linked neurodevelopmental disorder characterised by intellectual disability, developmental delays, anxiety, and social and behavioural challenges. Currently, no effective treatments exist to address the root cause of FXS. Mouse models are the most widely used for studying molecular pathogenesis and conducting preclinical treatment testing. However, therapeutic interventions that show promise in rodent models have yet to succeed in clinical trials. After evaluating the current models, we have developed an ovine model to address this clinical translation gap. We expect this model to more accurately reflect the human condition in brain size, structure, and neurodevelopmental trajectory. We aim to establish this model as a valuable preclinical platform for testing therapies for FXS.
Methods:
To generate the sheep model, we used CRISPR-Cas9 dual-guide editing to knock out the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene in ovine embryos.
Results:
Two founder animals were created, one ram (male) and one ewe (female), both of which carried FMR1 gene knockouts. The ewe carries inactivating mutations on both alleles, with the edits in both animals resulting in no detectable Fragile X Messenger Ribonucleoprotein (FMRP) as expected. Both founders have undergone molecular characterisation and basic health checks, with the female founder showing increased joint flexibility, a characteristic of FXS. The ram has been used for breeding, with the successful transmission of the edited allele to his offspring. Importantly, specific lamb cohorts for postnatal treatment testing can be produced efficiently utilising accelerated breeding methods and preimplantation selection.
Insights
Researchers developed a novel ovine model for Fragile X Syndrome (FXS) by knocking out the FMR1 gene. This new model aims to improve preclinical testing for FXS therapies, addressing limitations of current rodent models.
Area of Science:
- Neuroscience
- Genetics
- Animal Models
Background:
- Fragile X Syndrome (FXS) is a leading genetic cause of intellectual disability and autism spectrum disorder.
- Current FXS treatments do not address the underlying genetic cause.
- Existing rodent models show limited success in predicting human therapeutic outcomes.
Purpose of the Study:
- To develop a novel ovine model for Fragile X Syndrome (FXS).
- To create a preclinical platform that more accurately reflects human neurodevelopmental trajectory for FXS.
- To bridge the clinical translation gap in FXS therapeutic development.
Main Methods:
- Utilized CRISPR-Cas9 dual-guide gene editing in ovine embryos.
- Targeted the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene for knockout.
- Generated FMR1 knockout founder sheep (ram and ewe).
Main Results:
- Successfully created two FMR1 knockout founder sheep, confirmed by molecular characterization.
- Founder ewe exhibited increased joint flexibility, a characteristic associated with FXS.
- Demonstrated efficient breeding of the FMR1 knockout allele to offspring for future studies.
Conclusions:
- The ovine model accurately recapitulates FMR1 gene knockout and key FXS phenotypes.
- This model offers a promising preclinical platform for evaluating FXS therapies.
- Accelerated breeding and preimplantation selection enable efficient generation of study cohorts.
More Related Videos
08:22A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
Published on: September 16, 2019
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Related Concept Videos
X-linked Traits
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
X-Inactivation